Bradley Duffy

Array ( [id] => 10919215 [patent_doc_number] => 20140322233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS' [patent_app_type] => utility [patent_app_number] => 14/293802 [patent_app_country] => US [patent_app_date] => 2014-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 60832 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14293802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10769074 [patent_doc_number] => 20160115231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'TREATMENT OF MAST CELL RELATED PATHOLOGIES' [patent_app_type] => utility [patent_app_number] => 14/889851 [patent_app_country] => US [patent_app_date] => 2014-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 17879 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14889851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11277102 [patent_doc_number] => 09493579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Multivalent antibodies and uses therefor' [patent_app_type] => utility [patent_app_number] => 14/229683 [patent_app_country] => US [patent_app_date] => 2014-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 88 [patent_figures_cnt] => 133 [patent_no_of_words] => 44815 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14229683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14977923 [patent_doc_number] => 10442862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents [patent_app_type] => utility [patent_app_number] => 14/775117 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 11 [patent_no_of_words] => 19103 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14775117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685864 [patent_doc_number] => 20160032009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'HIGH AFFINITY ANTI-GD2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/776298 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 47783 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14776298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685840 [patent_doc_number] => 20160031985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/776157 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 88907 [patent_no_of_claims] => 349 [patent_no_of_ind_claims] => 189 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14776157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806528 [patent_doc_number] => 20160152686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'FIBRONECTIN BASED SCAFFOLD DOMAINS LINKED TO SERUM ALBUMIN OR MOIETY BINDING THERETO' [patent_app_type] => utility [patent_app_number] => 14/774229 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 29031 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14774229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9739769 [patent_doc_number] => 20140275488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/204295 [patent_app_country] => US [patent_app_date] => 2014-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 21523 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14204295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10522722 [patent_doc_number] => 09249220 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-02 [patent_title] => 'Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof' [patent_app_type] => utility [patent_app_number] => 14/204309 [patent_app_country] => US [patent_app_date] => 2014-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 35 [patent_no_of_words] => 21518 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14204309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14700167 [patent_doc_number] => 10377817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Human antibodies to GREM1 [patent_app_type] => utility [patent_app_number] => 14/775637 [patent_app_country] => US [patent_app_date] => 2014-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26389 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14775637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9615687 [patent_doc_number] => 20140205544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-24 [patent_title] => 'Cancer Treatment Comprising Therapeutics That Bind To Phosphatidylserine' [patent_app_type] => utility [patent_app_number] => 14/197672 [patent_app_country] => US [patent_app_date] => 2014-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 70515 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14197672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9546986 [patent_doc_number] => 20140171634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA' [patent_app_type] => utility [patent_app_number] => 14/185783 [patent_app_country] => US [patent_app_date] => 2014-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17741 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14185783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12962692 [patent_doc_number] => 09873747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-23 [patent_title] => Fusion proteins that facilitate cancer cell destruction [patent_app_type] => utility [patent_app_number] => 14/763701 [patent_app_country] => US [patent_app_date] => 2014-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15136 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14763701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15306509 [patent_doc_number] => 10517936 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Vaccines with higher carbohydrate antigen density and novel saponin adjuvant [patent_app_type] => utility [patent_app_number] => 14/758319 [patent_app_country] => US [patent_app_date] => 2014-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 14 [patent_no_of_words] => 7368 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14758319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10567414 [patent_doc_number] => 09290571 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => 'Antibodies to EphA3' [patent_app_type] => utility [patent_app_number] => 14/143427 [patent_app_country] => US [patent_app_date] => 2013-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 6 [patent_no_of_words] => 17867 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14143427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099231 [patent_doc_number] => 09856319 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Monovalent binding proteins' [patent_app_type] => utility [patent_app_number] => 14/141503 [patent_app_country] => US [patent_app_date] => 2013-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 42773 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14141503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9597915 [patent_doc_number] => 20140194596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'Dual Specificity Antibody Fusions' [patent_app_type] => utility [patent_app_number] => 14/101083 [patent_app_country] => US [patent_app_date] => 2013-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15347 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14101083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9537151 [patent_doc_number] => 20140161798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-12 [patent_title] => 'ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/094560 [patent_app_country] => US [patent_app_date] => 2013-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 23838 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14094560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9602610 [patent_doc_number] => 20140199293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'HUMANIZED ANTIBODY COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID' [patent_app_type] => utility [patent_app_number] => 14/084593 [patent_app_country] => US [patent_app_date] => 2013-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 58810 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14084593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9421724 [patent_doc_number] => 20140106374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-17 [patent_title] => 'ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/078241 [patent_app_country] => US [patent_app_date] => 2013-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 116882 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14078241 [rel_patent_id] =>[rel_patent_doc_number] =>)